Eli Lilly Reports Detailed Results From Phase 3 SURMOUNT-1 Three-year Study; Says Tirzepatide In Adults With Pre-diabetes And Obesity Or Overweight Resulted In Sustained Weight Loss And Nearly 99% Remained Diabetes-Free At 176 Weeks

Benzinga · 11/13/2024 22:11

Tirzepatide demonstrated sustained average weight loss of 22.9% (15 mg dose) through the three-year treatment period for the efficacy estimandi. These findings were published in The New England Journal of Medicine (NEJM) and recently presented at ObesityWeek 2024.